Cambridge, MA-based Cedilla Therapeutics is ‘discovering and exploiting’ insights into protein stability, according to the company, and generating therapeutics that degrade protein targets.
Sunil Shah, CEO of o2h Discovery, said it will be providing “the heavy lifting in medicinal chemistry and biological profiling,” as part of the collaboration.
“The goal is to achieve a drug candidate,” he told us.
Additionally, Shah noted that Karyopharm, for which o2h provides similar support, recently received US Food and Drug Administration (FDA) approval for oral Xpoviotm (selinexor), in combination with dexamethasone, as a new treatment for relapsed or refractory multiple myeloma.
An integrated drug discovery platform, o2h Discovery operates from its research center in India and The Mill SciTech Park, in Cambridge, UK.
The company, founded in 2005, also has launched its proprietary ‘AI Chemistry in the Cloud’ (AI-CITC) application, which enables communication between various scientific stakeholders.
